Metapristone (RU486 metabolite) suppresses NSCLC by targeting EGFR-mediated PI3K/AKT pathway

Therapies targeting epidermal growth factor receptor (EGFR) can effectively treat with non-small cell lung cancer (NSCLC), but NSCLC’s drug resistance makes it intractable. Herein, we showed that RU486 metabolite metapristone inhibited the proliferation of various NSCLC cell lines with either wild (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Shao, Jingwei, Zheng, Guirong, Chen, Hongning, Liu, Jian, Xu, Aixiao, Chen, Fan, Li, Tao, Lu, Yusheng, Xu, Jianguo, Zheng, Ning, Jia, Lee
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5667967/
https://ncbi.nlm.nih.gov/pubmed/29108234
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.18640
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados